Navigation Links
Ikaria® Names New Chief Financial Officer
Date:7/8/2010

CLINTON, N.J., July 8 /PRNewswire/ -- Ikaria, Inc. today announced that Craig Tooman will join Ikaria as Senior Vice President and Chief Financial Officer (CFO).  In this role, Mr. Tooman will be responsible for all financial functions of the company, as well as for information technology services.  Mr. Tooman succeeds Elizabeth Larkin, who left the company in March to pursue other interests.  He will assume his new role at the beginning of August.

"I am delighted that Craig will join us in this key executive role, and am confident that we will benefit greatly from his knowledge and experience in effectively managing the financial aspects of our business," commented Daniel Tasse, Chairman and CEO of Ikaria. "I believe that Craig's expertise -- combined with our product pipeline and commercial capabilities -- will help us achieve our vision of becoming a leader in critical care.  I also wish to thank Liz for building a strong foundation from which we can build."

Mr. Tooman has over 20 years of experience in the pharmaceutical industry, and joins Ikaria from Enzon Pharmaceuticals, where he was Executive Vice President of Finance and CFO since 2005.  Prior to joining Enzon, he served as Senior Vice President of Strategic Planning and Corporate Communications at ILEX Oncology, Inc., which was acquired by Genzyme in 2004.  He also played a significant role in the 2001 merger between Pharmacia & Upjohn and Monsanto that created the Pharmacia Corporation, having served in various positions within its predecessor companies Pharmacia & Upjohn and The Upjohn Company.  Mr. Tooman holds an MBA from the University of Chicago, and a BA from Kalamazoo College.

About Ikaria, Inc.

Ikaria, Inc. is a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to address the significant unmet needs of critically ill patients.  The company's lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies.  INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering, is the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants.  INOtherapy also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan.  Ikaria acquired the North American and Australian rights to LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as the exclusive worldwide license to IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction.  The company also has a number of investigational compounds in development.  Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA.  Please visit www.ikaria.com.


'/>"/>
SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
2. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
3. Xytis Names Gordon H. Busenbark as Chief Financial Officer
4. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
5. Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect
6. California Cryobank Names Richard Jennings President of FamilyCord Division
7. Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO
8. ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post
9. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
10. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
11. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , May 2, 2016  Deerfield announced ... financing of Graybug Vision, Inc. Graybug Vision is ... therapies that may transform care for ocular diseases ... Graybug Vision,s technology was first developed at Johns ... a startup venture. Graybug Vision ...
(Date:4/29/2016)... April 29, 2016  In the next ten ... shift from systems dependent on CRTs monitors to those ... modality CRT Medical monitors and will automatically sync ... host of foreseeable benefits to this technological advancement, ... modalities have to be replaced in order to ...
(Date:4/29/2016)... , April 29, 2016 ... glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years clinical ... and biotechnology industries. His last role was at Mologen ... of the Executive Board. Previously Dr. Zurlo held various ...
Breaking Medicine Technology:
(Date:5/2/2016)... Las Vegas, NV (PRWEB) , ... May 02, ... ... with Specialty Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award ... be determined based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy ...
(Date:5/2/2016)... , ... May 02, 2016 ... ... report that many commonly used prescription medications, including anxiolytics, painkillers, antidepressants and ... these risks, Novus Medical Detox Center —a leading Florida-based drug treatment ...
(Date:5/2/2016)... ... May 02, 2016 , ... TeleMedCo™, a new company developing ... and improve the rapid diagnosis, triage and admission of patients leveraging IBM Watson’s ... mobile experience for the first time at GENBAND’s Perspectives16 conference. , TeleMedCo ...
(Date:5/2/2016)... ... May 02, 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased to ... Could Transform the Pharma Landscape .” CMS recently proposed a test of alternate payment ... drugs while preserving care provided to beneficiaries. The webinar will review the details of ...
(Date:5/2/2016)... ... May 02, 2016 , ... The debilitating disease of arthritis ... With no cure, most patients must deal with prescription costs to treat arthritis over ... up to 75% savings at the pharmacy on many common prescriptions. , Arthritis , ...
Breaking Medicine News(10 mins):